Accueil   Diary - News   All news Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows

Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows


 

 

  • U.S. team of more than 100 specialist sales representatives & seasoned management in place

 

  • On track with clinical, regulatory, financial, and commercial milestones

 

 

Saint-Priest, France, May 2, 2018 – Biom'up (EPA: BUP), a specialist in surgical hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large number of independent specialist sales representatives to drive the nationwide marketing and sales campaign of HEMOBLAST Bellows, which is expected to start in mid-2018.



Etienne Binant, Chief Executive Officer, said: “Under the leadership of Dave Clark, U.S. Vice President of Sales, and Steven Ford, U.S. Vice President of Marketing, we have swiftly built a dedicated national hybrid sales organization. With a large team of specialists now in place, and given its clinically demonstrated high value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of hemostasis in operating rooms across the USA. Biom’up is now perfectly positioned to pursue its growth ambitions and transition towards a fully-fledged commercial organization.

 

 

Read the full press release